GuruFocus

08 Jun 2026, 23:24 UTC · 2h ago

Liquidia Corp (LQDA) Stock Up 3.4% and Still Undervalued -- GF Score: 75/100

Read original · https://www.gurufocus.com/news/8906318/liquidia-corp-lqda-stock-up-34-and-still-undervalued-gf-score-75100

Search tags

Story key points

0 claims · impact-rated

What matters in this story

No key-points head found for this article.

Ticker attribution

Model heads

Sentiment in this article

LQDA+0.60
The company's shares rose 3.4% and it is maintaining a strong performance trend.

Relationships in this article

No ticker relationship head found.

Early access

You’re reading about it. Someone else is already positioned.

News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.

LQDA

Browse live screenings

Impact vectors

1 dimensions · 9 clusters

Analytical profile by cluster

Valuation & Positioning+0.200

6 related stories

Seeking Alpha
4h ago
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- biotech
- pharmaceuticals
Read

Liquidia Corp (LQDA) Stock Up 3.4% and Still Undervalued -- GF Score:… · News Impact Screener

Liquidia Corp (LQDA) Stock Up 3.4% and Still Undervalued -- GF Score: 75/100

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Liquidia Corp (LQDA) Stock Up 3.4% and Still Undervalued -- GF Score: 75/100

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Top impact dimensions

Most positively impacted

Most negatively impacted

Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma

Is Altimmune Worth Buying Ahead of 2026 Catalysts?

GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Nurix Therapeutics Stock Pops on Roche Partnership

Liquidia Corp (LQDA) Stock Up 3.4% and Still Undervalued -- GF Score: 75/100

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Next reads from the same story arc

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Liquidia Corp (LQDA) Stock Up 3.4% and Still Undervalued -- GF Score: 75/100

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Next reads from the same story arc

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Top impact dimensions

Most positively impacted

Most negatively impacted

Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma

Is Altimmune Worth Buying Ahead of 2026 Catalysts?

GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Nurix Therapeutics Stock Pops on Roche Partnership